Navidea Biopharmaceuticals, Inc. NAVBQ
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 6.03M | -1.48M | -3.48M | -5.71M | -3.00M |
| Total Depreciation and Amortization | 27.10K | 27.60K | 26.50K | 24.70K | 21.80K |
| Total Amortization of Deferred Charges | 105.20K | 92.20K | 80.70K | 70.70K | 56.20K |
| Total Other Non-Cash Items | 161.70K | -1.15M | 241.00K | 104.90K | 92.20K |
| Change in Net Operating Assets | -1.64M | 779.50K | 701.30K | 3.65M | 690.00K |
| Cash from Operations | 4.69M | -1.72M | -2.43M | -1.86M | -2.14M |
| Capital Expenditure | 0.00 | -15.10K | 0.00 | -14.40K | -6.60K |
| Sale of Property, Plant, and Equipment | 300.00 | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -65.30K | -24.30K | -72.00K | -64.50K | -114.60K |
| Cash from Investing | -65.00K | -39.40K | -72.00K | -78.90K | -121.20K |
| Total Debt Issued | 300.00K | -- | 0.00 | 1.00M | 1.50M |
| Total Debt Repaid | -504.50K | -200.50K | -64.70K | 0.00 | -114.00K |
| Issuance of Common Stock | 643.80K | -- | 0.00 | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 1.10M | -- | 0.00 | 6.17M | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -54.60K | -- | -35.10K | -963.30K | -14.60K |
| Cash from Financing | 1.48M | -200.50K | -99.80K | 6.21M | 1.37M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.11M | -1.96M | -2.60M | 4.27M | -889.10K |